

Increased Mortality in Low-Volume Hospitals Performing Revision Arthroplasty for Periprosthetic Joint Infection of the Hip and Knee

Julian Wier, Avinash S Iyer, McKenzie Watts Culler, Sagar Telang, Ryan Christopher Palmer, Jay R Lieberman, Nathanael D Heckmann

INTRODUCTION: The relationship between hospital case volume and postoperative morbidity following revision arthroplasty for periprosthetic joint infection (PJI) has not been defined. As such, we sought to assess 90-day postoperative mortality among patients undergoing stage-one antibiotic spacer placement for PJI of the hip or knee at low-volume and high-volume hospitals.

METHODS: The Premier Healthcare Database was queried from 2015 to 2023 for adult patients undergoing stage-one antibiotic spacer placement for PJI. Using International Classification of Disease, Tenth Revision, Current Procedural Terminology codes, and hospital charge codes for antibiotics/spacers, patients undergoing stage-one arthroplasty for PJI were identified. A single volume threshold was identified via the Metropolis-Hastings algorithm using a Markov Chain Monte Carlo simulation of a restricted cubic spline (RCS) model on the odds of mortality over hospital volume to define low and high-volume. Patients who underwent surgery at high-volume hospitals were compared to those who underwent surgery at low-volume hospitals. Multivariable logistic regression was performed to assess odds of 90-day mortality while accounting for confounding factors. A p-value < 0.05 was considered significant.

RESULTS: In total, 61,527 PJI patients were used to construct a RCS which demonstrated that postoperative mortality was increased among patients who underwent surgery at low-volume hospitals performing <35 spacers annually. Mortality within 90 days of surgery was higher among the low-volume cohort (1.80% vs. 1.26%), even after accounting for confounding factors (adjusted odds ratio (aOR)=1.32; 95% Confidence Interval (CI)=1.13-1.54). Furthermore, low-volume hospitals had significantly higher rates (17.70% vs. 13.61%) and adjusted odds (aOR=1.45; 95% CI=1.37-1.52) of sepsis.

DISCUSSION AND CONCLUSION:

Patients who underwent spacer placement at a hospital performing <35 stage-one spacers annually had a >30% odds of postoperative mortality and sepsis.

Figure 1: Restricted cubic spline modeling the adjusted odds of 90-day mortality by annual hospital volume. Gray dashed lines represent the 95% confidence interval and the solid gray line represents the trend line.




Table 1: Primary and secondary study outcomes. (aOR=adjusted odds ratio, CI=confidence interval)

| Complication | High Volume N = 18,727 | | Low Volume N = 36,943 | | P-Value | Multivariate Regression | | |
|----------------------|---------------------------|--------|--------------------------|--------|---------|-------------------------|-----------|---------|
| | N | % | N | % | | aOR | 95%-CI | P-Value |
| 90-day Mortality | 238 | 1.27% | 720 | 1.95% | <0.001 | 0.76 | 0.65-0.88 | <0.001 |
| Sepsis | 2,549 | 13.61% | 7,076 | 19.15% | <0.001 | 0.69 | 0.66-0.73 | <0.001 |
| Readmission | 2,814 | 15.03% | 4,971 | 13.46% | <0.001 | 1.08 | 1.02-1.15 | 0.010 |
| Medical Complication | 4,683 | 25.01% | 10,133 | 27.43% | <0.001 | 0.88 | 0.84-0.92 | <0.001 |